TY - JOUR
T1 - Predictors of occult nodal metastasis in colon cancer
T2 - Results from a prospective multicenter trial
AU - Wasif, Nabil
AU - Faries, Mark B.
AU - Saha, Sukamal
AU - Turner, Roderick R.
AU - Wiese, David
AU - McCarter, Martin D.
AU - Shen, Perry
AU - Stojadinovic, Alexander
AU - Bilchik, Anton J.
N1 - Funding Information:
Supported by Grant 2RO1CA090848-05A2 from the National Cancer Institute and by funding from the William Randolph Hearst Foundation (San Francisco, CA), The Joyce E. and Ben B. Eisenberg Foundation (Los Angeles, CA), Davidow Charitable Fund (Los Angeles, CA), the Sequouia Foundation , Mrs. Ruth Weil (Los Angeles, CA), the Rod Fasone Memorial Cancer Fund (Los Angeles, CA), and the Henry L. Guenther Foundation (Los Angeles, CA).
PY - 2010/3
Y1 - 2010/3
N2 - Background: The relationship between primary colon cancer and occult nodal metastases (OMs) detected by cytokeratin immunohistochemistry (CK-IHC) is unknown. We sought to investigate the correlation of clinicopathologic features of colon cancer with OMs and to identify predictors of OM. Methods: Patients with colon cancer from 5 tertiary referral cancer centers enrolled in a prospective trial of staging had standard pathologic analysis performed on all resected lymph nodes (using hematoxylin and eosin staining [H&E]). Nodes negative on H&E underwent CK-IHC to detect OMs, which were defined as micrometastases (N1mic) or isolated tumor cells (N0i+). Patients who were negative on both H&E and CK-IHC were defined as node negative (NN), and those positive on H&E were node positive (NP). The relationships between tumor characteristics and OMs were analyzed using the Kruskal-Wallis and the Fisher exact test. Results: OMs were identified in 23.4% (25/107) of patients. No significant differences were found in demographics, tumor location, tumor size, and number of nodes examined between groups. Compared with the NN group, patients with OMs had more tumors that were T3/T4 (72% vs 57%; P < .001), had tumors of higher grade (28% vs 12%; P = .022), and had tumors with lymphovascular invasion (16% vs 3%; P < .001). Conclusion: Adverse primary pathologic colon cancer characteristics correlate with OMs. In patients with negative nodes on H&E and stage T3/T4 colon cancer, lymphovascular invasion, or high tumor grade, consideration should be given to performing CK-IHC. The detection of OMs in this subset may influence decisions regarding adjuvant chemotherapy and risk stratification.
AB - Background: The relationship between primary colon cancer and occult nodal metastases (OMs) detected by cytokeratin immunohistochemistry (CK-IHC) is unknown. We sought to investigate the correlation of clinicopathologic features of colon cancer with OMs and to identify predictors of OM. Methods: Patients with colon cancer from 5 tertiary referral cancer centers enrolled in a prospective trial of staging had standard pathologic analysis performed on all resected lymph nodes (using hematoxylin and eosin staining [H&E]). Nodes negative on H&E underwent CK-IHC to detect OMs, which were defined as micrometastases (N1mic) or isolated tumor cells (N0i+). Patients who were negative on both H&E and CK-IHC were defined as node negative (NN), and those positive on H&E were node positive (NP). The relationships between tumor characteristics and OMs were analyzed using the Kruskal-Wallis and the Fisher exact test. Results: OMs were identified in 23.4% (25/107) of patients. No significant differences were found in demographics, tumor location, tumor size, and number of nodes examined between groups. Compared with the NN group, patients with OMs had more tumors that were T3/T4 (72% vs 57%; P < .001), had tumors of higher grade (28% vs 12%; P = .022), and had tumors with lymphovascular invasion (16% vs 3%; P < .001). Conclusion: Adverse primary pathologic colon cancer characteristics correlate with OMs. In patients with negative nodes on H&E and stage T3/T4 colon cancer, lymphovascular invasion, or high tumor grade, consideration should be given to performing CK-IHC. The detection of OMs in this subset may influence decisions regarding adjuvant chemotherapy and risk stratification.
UR - http://www.scopus.com/inward/record.url?scp=76749099673&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749099673&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2009.10.008
DO - 10.1016/j.surg.2009.10.008
M3 - Article
C2 - 20116081
AN - SCOPUS:76749099673
SN - 0039-6060
VL - 147
SP - 352
EP - 357
JO - Surgery (United States)
JF - Surgery (United States)
IS - 3
ER -